[PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view]

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• The immune checkpoint programmed death-ligand 1 (PD-L1) is a key target in cancer immunotherapy.
• Tumor cells exploit the PD-L1/PD-1 interaction to evade cytotoxic T-cell responses.
• Blocking this interaction can restore anti-tumor immunity.

Purpose of the Study:

• To emphasize the role of anatomopathology in the intratumoral detection of PD-L1.
• To discuss the implications of PD-L1 in neoplastic processes.
• To review therapeutic blockade principles and biomarker applications in pathological practice.

Main Methods:

• Focus on the mechanism of PD-L1 action.
• Exploration of PD-L1's role in cancer development.
• Analysis of therapeutic strategies targeting PD-1/PD-L1.
• Evaluation of biomarkers for treatment efficacy.

Main Results:

• PD-L1 expression is a critical factor in tumor immune evasion.
• Targeting PD-L1 can reactivate anti-tumor T-cell responses.
• Anatomopathological assessment is vital for PD-L1 biomarker utilization.

Conclusions:

• Anatomopathology plays a central role in identifying PD-L1 for immunotherapy.
• Understanding PD-L1 mechanisms and biomarkers optimizes anti-cancer treatment strategies.
• Accurate pathological assessment ensures effective application of PD-1/PD-L1 blockade therapies.